Table 2. Overall clinical response (end of cycle 6 or at early withdrawal).
|
Number (%) of patients |
|||||
|---|---|---|---|---|---|
| ITT (n=42) | CMML-1a (n=26) | CMML-2a (n=16) | dCMML (n=14) | pCMML (n=28) | |
| ORR | 20 (47.6) | 15 (57.6) | 5 (31.25) | 9 (64.3) | 11 (39.3) |
| CR | 7 (16.6) | 5 (19.2) | 2 (12.5) | 3 (21.4) | 4 (14.3) |
| mCR | 8 (19.0) | 6 (23.1) | 2 (12.5) | 4 (28.6) | 4 (14.3) |
| PR | 1 (2.4) | 0 (0.0) | 1 (6.2) | 0 (0.0) | 1 (3.5) |
| HI | 4 (9.5) | 4 (15.3) | 0 (0.0) | 2 (14.2) | 2 (7.2) |
| SD | 9 (21.4) | 4 (15.3) | 5 (31.3) | 0 (0.0) | 9 (32.1) |
| PD | 13 (31.0) | 7 (26.9) | 6 (37.5) | 5 (35.7) | 8 (28.6) |
Abbreviations: CR, complete response; CMML, CMML, chronic myelomonocytic leukemia; dCMML, dysplastic CMML; HI, hematological improvement; ITT, intent-to-treat; ORR, overall response rate; mCR, marrow CR; pCMML, proliferative CMML; PD, progressive disease; PR, partial remission; SD, stable disease; WHO, World Health Organization.
Percentages may not total 100 owing to rounding.
a
Defined according to the 2008 edition of the WHO classification of tumors of the hematopoietic and lymphoid tissue.